New Review describes the importance of deubiquitylases (DUBs) as key drug targets

A Review, published today in Nature Reviews Drug Discovery, highlights deubiquityating enzymes as key drug discovery targets. The paper is co-authored by Mission Therapeutics co-founders Steve Jackson, Niall Martin and scientists Xavier Jacq and Jeanine Harrigan. The full paper can be read here